CTLA4 and neoplasm: At the clinical level, evading immune destruction involves in the elevation of immunosuppressive cells (e.g., TAMs and Treg cells), the expression of immune checkpoint molecules (e.g., CTLA-4 and PD-L1), and the reduction of mutation-derived tumor neoantigens46–48.